Xeloda, Capecitabine Newswire (Page 2)

Xeloda, Capecitabine Newswire (Page 2)

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic). (Page 2)

Results 21 - 40 of 179 in Xeloda, Capecitabine (generic)

  1. Researchers identify potential target for treatment of aggressive brain cancerRead the original story w/Photo

    Jun 7, 2017 | PhysOrg Weblog

    Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme , the most malignant cancer of the brain. Specifically, the study, led by Professor H. Phillip Koeffler, Senior Principal Investigator at CSI Singapore, found that GBM patients with lower levels of the BCL6 protein have a higher survival rate than those with high BCL6 expression.

    Comment?

  2. How have HPV vaccines affected cervical cancer screening?Read the original story w/Photo

    Jun 7, 2017 | PhysOrg Weblog

    A new review looks at cervical cancer screening in the era of HPV vaccination. The review notes that trials have demonstrated the efficacy and safety of vaccines against HPV infection, but the complete effect of HPV vaccination as a cancer prevention strategy may not be fully evident for decades, given the slow progression from HPV infection to the development of cervical cancer.

    Comment?

  3. Puma Biotech Announces Positive PB272 Phase II Data From TBCRC 022...Read the original story

    Jun 4, 2017 | BioSpace

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The data were presented today in an oral presentation at the American Society of Clinical Oncology 2017 Annual Meeting in Chicago, Illinois.

    Comment?

  4. Lynparza significantly reduces the risk of disease worsening or death ...Read the original story

    Jun 4, 2017 | PressReleasePoint

    OlympiAD was the first positive Phase III trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza tablets , compared to treatment with physician's choice of a standard of care chemotherapy. In addition to meeting its primary endpoint of PFS assessed by blinded independent central review , the trial showed that patients treated with Lynparza had a 42% reduction in risk of their disease worsening or death compared to those who received chemotherapy .

    Comment?

  5. LYNPARZAa (olaparib) Significantly Reduces the Risk of Disease...Read the original story

    Jun 4, 2017 | Customer Interaction Solutions

    AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with LYNPARZATM tablets , compared to treatment with physician's choice of a standard of care chemotherapy.

    Comment?

  6. Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC...Read the original story

    Jun 3, 2017 | Customer Interaction Solutions

    Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The data were presented today in an oral presentation at the American Society of Clinical Oncology 2017 Annual Meeting in Chicago, Illinois.

    Comment?

  7. Puma Biotechnology announces positive trial resultsRead the original story w/Photo

    Jun 3, 2017 | Seeking Alpha

    Puma Biotechnology presents at ASCO the positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases.

    Comment?

  8. Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyRead the original story

    Jun 3, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  9. Drug Xeloda Prolongs Survival for Some Breast Cancer PatientsRead the original story w/Photo

    Jun 1, 2017 | MedicineNet

    A drug called Xeloda can extend the lives of some women whose breast cancer is not wiped out by standard treatment, a new clinical trial finds. "This drug is already approved, and we've been using it for a long time in cancer treatment," said Dr. Stephen Malamud, an oncologist at Mount Sinai in New York City.

    Comment?

  10. Switch in KRAS mutational status during an unusual course of disease...Read the original story w/Photo

    May 25, 2017 | BioMed Central

    Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in the KRAS gene might play a prognostic role regarding overall survival and may also have the potential to predict the efficacy of anti-EGFR treatment.

    Comment?

  11. Association of thymidylate synthase polymorphisms with the tumor...Read the original story

    May 21, 2017 | The Pharmacogenomics Journal

    95 Yongan Road, Xi-Cheng District, Beijing 100050, China. E-mail: [email protected] or [email protected] Preoperative chemoradiotherapy followed by surgery is currently the standard therapy for patients with locally advanced rectal cancer.

    Comment?

  12. Chemo Drug May Buy Time for Those With Bile Duct CancerRead the original story w/Photo

    May 19, 2017 | MedicineNet

    The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer , a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months longer than those who didn't take it, the researchers found.

    Comment?

  13. MultiVir Reports Gene Therapy Enhancement of Cancer ImmunotherapyRead the original story w/Photo

    May 18, 2017 | BioSpace

    These results were obtained in a melanoma animal tumor model known to be highly resistant to immunotherapy including the new class of agents termed immune checkpoint inhibitors. While immune checkpoint inhibitors represent an important breakthrough in cancer treatment, most patients do not respond to these therapies and novel approaches are needed to reverse this resistance.

    Comment?

  14. Oral chemotherapy extends survival by more than a year in biliary tract cancerRead the original story w/Photo

    May 16, 2017 | EurekAlert!

    A phase III randomized clinical trial of 447 patients with biliary tract cancers showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease.

    Comment?

  15. ASLAN Release: New Data On Varlitinib Published At 2017 Annual Meeting Of ASCORead the original story

    May 17, 2017 | BioSpace

    Singapore, 18 May 2017 - ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that new data on its lead asset, varlitinib, has been accepted by the American Society of Cancer Oncology for publication at its 2017 annual meeting. The meeting will take place from 2 - 6 June at the McCormick Place Convention Centre in Chicago, Illinois.

    Comment?

  16. Drug improves survival of patients with rare cancer by almost a quarterRead the original story w/Photo

    May 17, 2017 | PhysOrg Weblog

    Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK funded trial presented at the 2017 ASCO Annual Meeting in Chicago. The BILCAP trial is one of the first to look at testing treatments for bile duct cancer following surgery .

    Comment?

  17. Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual MeetingRead the original story

    May 17, 2017 | Customer Interaction Solutions

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 that will be presented at the American Society of Clinical Oncology Annual Meeting, which will be held June 2-6, 2017, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org .

    Comment?

  18. Conjugate drug extends survival in patients with advanced HER2-positive breast cancer, trial showsRead the original story

    May 16, 2017 | PressReleasePoint

    Women with HER2-positive breast cancer that worsened after previous treatment, survived significantly longer, on average, with a combination antibody/chemotherapy drug than with other treatments, an international phase 3 clinical trial led by researchers at Dana-Farber Cancer Institute and in Belgium has found. The results, reported online today by The Lancet Oncology , solidify the role of the combination drug, trastuzumab emtansine, in treating this group of patients, the study authors say.

    Comment?

  19. Clinical benefit of adding oxaliplatin to standard neoadjuvant...Read the original story w/Photo

    May 11, 2017 | BioMed Central

    Neoadjuvant fluoropirimidine -based chemoradiotherapy has been considered the standard of care for locally advanced rectal cancer . Whether addition of oxaliplatin will further improve clinical outcomes is still debated.

    Comment?

  20. Cascadian Therapeutics' (CASC) CEO Scott Myers on Q1 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    May 9, 2017 | Seeking Alpha

    Good day, ladies and gentlemen, and welcome to the Cascadian Therapeutics First Quarter 2017 Financial Results Conference Call. At this time all participants are in a listen-only mode.

    Comment?